GRACE principles: recognizing high-quality observational studies of comparative effectiveness.

Nonrandomized comparative effectiveness studies contribute to clinical and biologic understanding of treatments by themselves, via subsequent confirmation in a more targeted randomized clinical trial, or through advances in basic science. Although methodological challenges and a lack of accepted principles to assess the quality of nonrandomized studies of comparative effectiveness have limited the practical use of these investigations, even imperfect studies can contribute useful information if they are thoughtfully designed, well conducted, carefully analyzed, and reported in a manner that addresses concerns from skeptical readers and reviewers. The GRACE (Good Research for Comparative Effectiveness) principles have been developed to help healthcare providers, researchers, journal readers, and editors evaluate the quality inherent in observational research studies of comparative effectiveness. The GRACE principles were developed by experienced academic and private sector researchers and were vetted over several years through presentation, critique, and consensus building among outcomes researchers, pharmacoepidemiologists, and other medical scientists and via formal review by the International Society of Pharmacoepidemiology. In contrast to other documents that guide systematic review and reporting, the GRACE principles are high-level concepts about good practice for nonrandomized comparative effectiveness research. The GRACE principles comprise a series of questions to guide evaluation. No scoring system is provided or encouraged, as interpretation of these observational studies requires weighing of all available evidence, tempered by judgment regarding the applicability of the studies to routine care.

[1]  Jan P Vandenbroucke,et al.  STREGA, STROBE, STARD, SQUIRE, MOOSE, PRISMA, GNOSIS, TREND, ORION, COREQ, QUOROM, REMARK... and CONSORT: for whom does the guideline toll? , 2009, Journal of clinical epidemiology.

[2]  A. Hartz,et al.  A comparison of observational studies and randomized, controlled trials. , 2000, The New England journal of medicine.

[3]  N. Dreyer,et al.  Registries for Evaluating Patient Outcomes: A User’s Guide , 2010 .

[4]  Timothy L. Lash,et al.  Applying Quantitative Bias Analysis to Epidemiologic Data , 2009, Statistics for Biology and Health.

[5]  Elliott S Fisher,et al.  Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. , 2007, JAMA.

[6]  G. Gravlee Aprotinin during Coronary-Artery Bypass Grafting and Risk of Death , 2009 .

[7]  M Alan Brookhart,et al.  Instrumental Variable Analysis of Secondary Pharmacoepidemiologic Data , 2006, Epidemiology.

[8]  K. Rothman,et al.  Mortality in current and former users of clozapine , 1996, Schizophrenia Research.

[9]  Clarence Balden Randall,et al.  Report to the President and the Congress , 1954 .

[10]  G. Guyatt,et al.  Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.

[11]  W. Ray,et al.  Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.

[12]  F. Song,et al.  Evaluating non-randomised intervention studies. , 2003, Health technology assessment.

[13]  Michael L. Johnson,et al.  Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  S. Potkin,et al.  The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. , 2004, Schizophrenia bulletin.

[15]  Dawei Xie,et al.  Replicated studies of two randomized trials of angiotensin‐ converting enzyme inhibitors: further empiric validation of the ‘prior event rate ratio’ to adjust for unmeasured confounding by indication , 2008, Pharmacoepidemiology and drug safety.

[16]  Til Stürmer,et al.  Indications for propensity scores and review of their use in pharmacoepidemiology. , 2006, Basic & clinical pharmacology & toxicology.

[17]  David Atkins,et al.  Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[18]  W. Baine,et al.  The Agency for Healthcare Research and Quality , 2006, Italian Journal of Public Health.

[19]  I. Persson,et al.  European Medicines Agency review of post‐authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance , 2011, Pharmacoepidemiology and drug safety.

[20]  Canary Wharf,et al.  The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) , 2012 .

[21]  J. Avorn,et al.  Increasing Levels of Restriction in Pharmacoepidemiologic Database Studies of Elderly and Comparison With Randomized Trial Results , 2007, Medical care.

[22]  M Alan Brookhart,et al.  Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. , 2005, American journal of epidemiology.

[23]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[24]  Matthias Egger,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies , 2007, PLoS medicine.

[25]  J. Concato,et al.  Randomized, controlled trials, observational studies, and the hierarchy of research designs. , 2000, The New England journal of medicine.

[26]  H. Tilson,et al.  The Antiretrovirals in Pregnancy Registry: A Fifteenth Anniversary Celebration , 2007, Obstetrical & gynecological survey.

[27]  M. Epstein,et al.  Guidelines for good pharmacoepidemiology practices (GPP) , 2008 .

[28]  H. Krumholz,et al.  Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator. , 2009, JAMA.

[29]  David A. Brodie,et al.  CLINICAL TRIALS VERSUS THE REAL WORLD: THE EXAMPLE OF CARDIAC REHABILITATION , 2008 .